19230-58-1

Usage

Uses

Used in Laboratory Research:
2-Bromo-5-Methylpyridine-1-oxide is used as a synthetic intermediate for the preparation of more complex organic compounds in laboratory settings. Its unique structure with a bromine atom and a methyl group on the pyridine ring allows for further chemical reactions and modifications, making it a valuable building block in organic synthesis.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, 2-Bromo-5-Methylpyridine-1-oxide is used as a key intermediate in the synthesis of various pharmaceutical compounds. Its presence in the molecular structure can impart specific biological activities and properties to the final drug molecules, contributing to their therapeutic effects.
Used in Chemical Synthesis:
2-Bromo-5-Methylpyridine-1-oxide is utilized as a versatile building block in chemical synthesis for the production of a wide range of organic compounds. Its reactivity and functional groups enable it to participate in various chemical reactions, such as nucleophilic substitution, electrophilic aromatic substitution, and cross-coupling reactions, leading to the formation of diverse organic molecules with potential applications in various fields.
Used in Material Science:
In the field of material science, 2-Bromo-5-Methylpyridine-1-oxide can be employed as a component in the development of novel materials with specific properties. Its incorporation into polymers, for instance, can result in materials with improved thermal stability, mechanical strength, or other desirable characteristics.
Overall, 2-Bromo-5-Methylpyridine-1-oxide is a versatile synthetic compound with a broad range of applications across various industries, primarily as an intermediate in the synthesis of more complex organic compounds and materials. Its unique structure and reactivity make it a valuable asset in the fields of pharmaceuticals, chemical synthesis, and material science.

Upstream product

• 3510-66-5 2-Bromo-5-methylpyridine 

Downstream Products

• 60323-98-0 2-bromo-5-methyl-4-nitropyridine N-oxide 
• 89466-16-0 6-bromo-3-methylpyridin-2-amine 
• 1350648-57-5 2-(3-fluoro-6-methylpyridin-2-yl)-5-methylpyridine 1-oxide 

Relevant academic research and scientific papers

HETEROARYL COMPOUNDS FOR TREATMENT OF COMPLEMENT FACTOR D MEDIATED DISORDERS

Compounds, methods of use, and processes for making inhibitors of complement factor D or a pharmaceutically acceptable salt or composition thereof are provided. The inhibitors described herein target factor D and inhibit or regulate the complement cascade. The inhibitors of factor D described herein reduce the excessive activation of complement.

OCULAR DRUG DEPOT FOR COMPLEMENT-MEDIATED DISORDERS

This disclosure provides an ocular tissue depot of a selected complement factor D (CFD) inhibitor for the extended treatment of an ocular disorder mediated by complement factor D. In particular, the disclosure includes the creation of a drug depot within the choroid-retina pigmented epithelium (C-RPE) and/or the iris-ciliary body (I-CB) of the eye by means of the systemic (oral or parenteral) administration of the compound, where the compound accumulates in ocular tissue and is released over an extended period for the treatment of a posterior and/or anterior eye disorder.

MORPHIC FORMS OF COMPLEMENT FACTOR D INHIBITORS

This invention provides stable, highly crystalline forms of Complement factor D inhibitors Compound 1 and Compound 2 for advantageous therapeutic pharmaceutical efficacy and dosage form stability.

Towards Identification of Essential Structural Elements of Organoruthenium(II)-Pyrithionato Complexes for Anticancer Activity

An organoruthenium(II) complex with pyrithione (2-mercaptopyridine N-oxide) 1 a has previously been identified by our group as a compound with promising anticancer potential without cytotoxicity towards non-cancerous cells. To expand the rather limited research on compounds of this type, an array of novel chlorido and 1,3,5-triaza-7-phosphaadamantane (pta) organoruthenium(II) complexes with methyl-substituted pyrithiones has been prepared. After thorough investigation of the aqueous stability of these complexes, their modes of action have been elucidated at the cellular level. Minor structural alterations in the ruthenium-pyrithionato compounds resulted in fine-tuning of their cytotoxicities. The best performing compounds, 1 b and 2 b, with a chlorido or pta ligand bound to ruthenium, respectively, and a methyl group at the 3-position of the pyrithione scaffold, have been further investigated. Both compounds trigger early apoptosis, induce the generation of reactive oxygen species and G1 arrest in A549 cancer cells, and show no strong interaction with DNA. However, only 1 b also inhibits thioredoxin reductase. Wound healing assays and mitochondrial function evaluation have revealed differences between these two compounds at the cellular level.

ARYL, HETEROARYL, AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS

Compounds, methods of use, and processes for making inhibitors of complement Factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof wherein R12 or R13 on the A group is an aryl, heteroaryl or heterocycle (R32) are provided. The inhibitors of Factor D described herein reduce the excessive activation of complement.

Exploring the influence of the protein environment on metal-binding pharmacophores

The binding of a series of metal-binding pharmacophores (MBPs) related to the ligand 1-hydroxypyridine-2-(1H)-thione (1,2-HOPTO) in the active site of human carbonic anhydrase II (hCAII) has been investigated. The presence and/or position of a single methyl substituent drastically alters inhibitor potency and can result in coordination modes not observed in small-molecule model complexes. It is shown that this unexpected binding mode is the result of a steric clash between the methyl group and a highly ordered water network in the active site that is further stabilized by the formation of a hydrogen bond and favorable hydrophobic contacts. The affinity of MBPs is dependent on a large number of factors including donor atom identity, orientation, electrostatics, and van der Waals interactions. These results suggest that metal coordination by metalloenzyme inhibitors is a malleable interaction and that it is thus more appropriate to consider the metal-binding motif of these inhibitors as a pharmacophore rather than a "chelator". The rational design of inhibitors targeting metalloenzymes will benefit greatly from a deeper understanding of the interplay between the variety of forces governing the binding of MBPs to active site metal ions.

PYRAZOLO[4,3-B]PYRIDINE-7-AMINE INHIBITORS OF ALK5

The present invention provides ALK5 inhibitors of the formula (I) wherein the variables are as defined herein. Also provided are pharmaceutical compositions, methods of making the compounds and intermediates thereof; and methods of using the compounds.

Magnesiation of pyridine N-oxides via iodine or bromine-magnesium exchange: A useful tool for functionalizing pyridine N-oxides

Iodo- or 2-bromopyridine N-oxides were readily magnesiated with i-PrMgCl ? LiCl via the iodine or bromine-magnesium exchange. The bromine adjacent to pyridine N-oxide (at the 2- or 6-position) can be regioselectively magnesiated in the presence of other position substituted halogens. This method was tested in various substituted pyridine N-oxide systems, and has been successfully applied to the total synthesis of caerulomycins E and A.